Abstract
Publisher Summary This chapter mentions preliminary work accomplished in both the clinic and the laboratory. Presently, this work is engaged on two fronts. The first is clinical empiricism, wherein positive, null, or untoward effects of one or another hormone in one or another condition suggest a trial of the hormone in another condition or of some other hormone in the same condition. The other front is the laboratory quest for mechanisms. Hypothalamic polypeptide releasing factors and release inhibiting factors appear to exert effects on brain other than their effects on the pituitary gland. These brain effects may have direct behavioral consequences. The exploitation of these properties of hypothalamic hormones for the treatment of illness has hardly begun. The chapter is astonished to find that the apparent benefits of Thyrotropin-releasing hormone (TRH) are not specific to a single diagnostic group. TRH is a hormone, not a drug. It probably influences a variety of functions, the alteration of which have behavioral consequences that can reasonably be regarded as improvement, or aggravation, in any diagnostic entity in which that function is involved. The effects of TRH are not diagnosis specific, but neither are behavioral deficits.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call